TLR4 and melanoma: Also, the treatment with pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-γ agonist inhibits the TLR4-mediated pro-inflammatory signaling, MyD88-mediated NF-κB activation in melanoma cells in vitro and suppresses melanoma in vivo (Dana et al., 2019[32], 2020[31]).